

# Contents

## Chapter 1 Histocompatibility Matching in Penetrating Keratoplasty

Daniel Böhringer, Thomas Reinhard

1.1	Introduction.....	1
1.2	Major Transplantation Antigens (HLA) .....	1
1.2.1	Typing Methods .....	2
1.2.2	Discussion of the Evidence for HLA Matching in Penetrating Keratoplasty.....	2
1.2.3	Differential HLA Matching .....	3
1.3	Minor (H) Transplantation Antigens .....	3
1.3.1	Discussion of Selected H Antigens .....	4
1.3.1.1	H-Y.....	4
1.3.1.2	HA-3 .....	4
1.3.1.3	ABO.....	5
1.4	Practical Concerns: Time on the Waiting List .....	5
1.4.1	Waiting Time Variability as a Major Handicap in HLA Matching.....	5
1.4.2	Predicting the Time on the Waiting List.....	5
1.5	Recommended Clinical Practice .....	6
	References .....	6

## Chapter 2 Acute Anterior Uveitis and HLA-B27: What's New?

John H. Chang, Peter J. McCluskey,  
Denis Wakefield

2.1	Introduction.....	9
2.2	Epidemiology of Acute Anterior Uveitis and HLA-B27 .....	10
2.2.1	Global Patterns of HLA-B27+ Acute Anterior Uveitis .....	10
2.3	HLA-B27 and Disease .....	10
2.3.1	New Developments in the Immunogenetics of HLA-B27.....	11
2.3.2	Role of Microbial Triggers in Immune-Mediated Inflammation .....	12

2.3.3	HLA-B27-Associated Inflammatory Disease .....	13
2.4	Other Genetic Risk Factors for Acute Anterior Uveitis .....	13
2.5	Current Understanding of AAU Pathogenesis.....	13
2.5.1	Cytokines .....	14
2.5.2	Toll-Like Receptors (TLR).....	14
2.6	Clinical Features of Acute Anterior Uveitis.....	15
2.6.1	HLA-B27 and Clinical Phenotype.....	15
2.6.2	Ocular Complications.....	15
2.7	Clinical Management of AAU.....	16
2.8	Conclusions .....	16
	References .....	17

## Chapter 3 What Can the Aqueous Humour Tell Us About Uveitis?

Alastair K.O. Denniston, S. John Curnow

3.1	Clinical Examination of the Aqueous Humour in Uveitis .....	19
3.1.1	Introduction .....	19
3.1.2	Observable Changes During Intraocular Inflammation .....	19
3.1.3	Sampling of Aqueous Humour.....	20
3.2	Identification of Infectious Agents in Aqueous Humour .....	21
3.2.1	Intraocular Antibody and PCR.....	21
3.2.2	Recent Technological Advances.....	21
3.3	Leukocyte Populations in Aqueous Humour .....	21
3.3.1	The Noninflamed Eye.....	21
3.3.2	Cytocentrifuge Analysis of Leukocyte Populations in Uveitis Aqueous Humour.....	21
3.3.3	Flow Cytometric Analysis of Uveitis Aqueous Humour.....	22
3.3.4	Antigen Specificity of Aqueous Humour T Cells .....	23
3.4	Changes in the Aqueous Humour Microenvironment During Episodes of Uveitis .....	23

3.4.1	Immunological Properties of Aqueous Humour .....	23
3.4.2	Cytokine Profiles of Aqueous Humour .....	23
3.4.3	IL-10 In Aqueous Humour .....	24
3.5	Summary and Future Directions .....	25
	References .....	25

#### Chapter 4

##### **Is Diabetic Retinopathy an Inflammatory Disease? Inflammation as a Stimulus for Vascular Leakage and Proliferation**

Antonia M. Joussen

4.1	Introduction .....	29
4.1.1	Clinical Problems and Cellular Interaction in Diabetic Retinopathy .....	29
4.1.2	Elevated Adhesion Molecules and Inflammatory Mediators in Diabetic Retinopathy .....	30
4.2	Inflammatory Processes Mediate Diabetic Macula Edema .....	31
4.2.1	Diabetic Vascular Leakage is Mediated by Inflammation .....	31
4.2.2	Diabetic Vascular Leakage Can Be Inhibited by Anti-inflammatory Agents .....	31
4.3	Inflammatory Aspects of Retinal Vascular Remodeling and Growth .....	32
4.3.1	Leukocytes Mediate Retinal Vascular Remodeling During Development and Vaso-Obliteration in Disease .....	32
4.3.2	Effects of VEGF on Ocular Neovascularisation and Vascular Permeability .....	33
4.4	Clinical Application of the Inflammatory Concept in Diabetic Retinopathy .....	34
4.4.1	Nonsteroidal Anti-inflammatory Drugs .....	34
4.4.2	Corticosteroids .....	34
4.4.3	Antiangiogenic Treatment .....	35
4.4.3.1	Phase 2 Trial: Intravitreal Pegaptanib as a Treatment for DME .....	35
4.4.3.2	Clinical Experience with Bevacizumab in Diabetic Retinopathy .....	37
4.4.3.3	Ranibizumab in Diabetic Macula Edema .....	38
	References .....	39

#### Chapter 5

##### **Steroid Sensitivity in Uveitis**

Richard W.J. Lee, Lauren P. Schewitz,  
Ben J.E. Raveney, Andrew D. Dick

5.1	Introduction .....	45
5.2	Glucocorticoids as Regulators of the Immune Response .....	45
5.2.1	Endogenous Glucocorticoids and the Hypothalamic–Pituitary–Adrenal Axis .....	45
5.2.2	Glucocorticoid Control of Cell Function .....	48
	485.2.3 . . The Interleukin-2/Glucocorticoid Balance .....	48
5.3	Glucocorticoids in the Treatment of Noninfectious Uveitis .....	48
5.4	Steroid Sensitivity in Other Inflammatory Diseases .....	49
5.4.1	The Concept of a Common Steroid Refractory Phenotype .....	49
5.5	Immune Mechanisms of Steroid Resistance .....	50
5.6	Future Directions: Novel Strategies to Optimise Glucocorticoid Treatment .....	52
5.6.1	Targeting Steroid Refractory Cd4 <sup>+</sup> Cd25 <sup>int</sup> Cells .....	52
5.6.2	Other Approaches .....	52
	References .....	52

#### Chapter 6

##### **Multiple Sclerosis and Uveitis**

Graeme J. Williams

6.1	Introduction .....	55
6.2	Association Between Multiple Sclerosis and Uveitis .....	55
6.3	Clinical Findings in MS-Associated Uveitis .....	56
6.4	Histopathological Findings .....	57
6.5	Experimental Models .....	58
6.6	Treatment .....	58
	References .....	58

#### Chapter 7

##### **Inflammation in Age-Related Macular Degeneration: What is the Evidence?**

Heping Xu, John V. Forrester

7.1	Introduction .....	61
7.2	Evidence from Clinical Studies .....	62
7.2.1	Genetic Link to Inflammation .....	62

7.2.2	Epidemiological Evidence for Inflammatory Markers in AMD .....	62	8.9	Retinal Transplantations .....	82
7.2.2.1	C-Reactive Protein (CRP) .....	62		References .....	82
7.2.2.2	IL-6 .....	62	<b>Chapter 9</b>		
7.2.2.3	Tumor Necrosis Factor- $\alpha$ (TNF- $\alpha$ ) .....	63	<b>Patterns of Retinal Vascular Involvement in the Diagnosis of Retinal Vasculitis</b>		
7.2.2.4	Intercellular Adhesion Molecule (ICAM)-1 .....	63	Miles R. Stanford, Rashmi Mathew		
7.2.2.5	Circulating White Blood Cell (WBC) Count .....	63	9.1	Introduction .....	87
7.2.2.6	Retinal Autoantibodies .....	63	9.2	Pathology of Retinal Vasculitis .....	88
7.2.2.7	Other Markers .....	63	9.2.1	General Pathology of Retinal Vessels .....	88
7.2.3	Inflammatory Components in Drusen .....	64	9.2.2	Pathology of Retinal Vessels in Specific Diseases .....	88
7.2.4	Evidence from Clinical Anti-inflammatory Treatment Studies .....	64	9.2.2.1	Behçet's Disease .....	88
7.3	Evidence from Experimental Studies .....	64	9.2.2.2	Tuberculosis .....	88
7.3.1	Myeloid Cells in the Pathogenesis of AMD .....	64	9.2.2.3	Sarcoidosis .....	89
7.3.1.1	Choroidal Monocytes in the Pathogenesis of AMD .....	64	9.2.2.4	Multiple Sclerosis .....	89
7.3.1.2	Retinal Microglia in the Pathogenesis of AMD .....	65	9.2.2.5	Idiopathic Isolated Retinal Vasculitis ..	89
7.3.2	Complement Activation in Age-Related Macular Degeneration .....	67	9.2.2.6	Acute Retinal Necrosis .....	89
7.4	Conclusion .....	68	9.2.2.7	Sympathetic Ophthalmia .....	89
	References .....	68	9.3	Clinical Features of Retinal Vasculitis .....	90
<b>Chapter 8</b>			9.3.1	Primary, Idiopathic, Isolated RV .....	90
<b>Age-Related Macular Degeneration: Immunological Factors in the Pathogenesis and Therapeutic Consequences</b>			9.3.2	Systemic Disease and RV .....	92
Aize Kijlstra, Ellen C. La Heij, Fleur Goezinne, Fred Hendrikse			9.3.2.1	Behçet's Disease .....	92
8.1	Introduction .....	73	9.3.2.2	Eales Disease .....	92
8.2	Inflammatory Cells in the Choroid and Retina in AMD .....	74	9.3.2.3	Tuberculosis .....	93
8.3	Infectious Pathogens and AMD .....	75	9.3.2.4	Sarcoidosis .....	93
8.4	Role of Autoimmunity in AMD .....	76	9.3.2.5	Multiple Sclerosis .....	93
8.5	Drusen as Triggers of Complement Activation in AMD .....	76	9.3.3	Retinal Vasculitis Associated with Infection .....	94
8.6	Genetic Factors Related to Inflammation and AMD .....	78	9.3.3.1	Viral Retinitis .....	94
8.7	Anti-inflammatory Effects of Nutritional Factors .....	79	9.3.3.2	Syphilis .....	95
8.8	Anti-inflammatory Drugs and AMD .....	80		References .....	95
8.8.1	Angiostatic Steroids .....	80	<b>Chapter 10</b>		
8.8.2	Antiangiogenic Therapy in AMD .....	81	<b>Masquerade Syndromes</b>		
8.8.3	Immunotherapy for AMD .....	81	Shouvik Saha, Elizabeth M. Graham		
			10.1	Introduction .....	97
			10.2	Lymphoproliferative Malignancies .....	97
			10.2.1	Primary Intraocular Lymphoma .....	97
			10.2.1.1	Introduction .....	97
			10.2.1.2	Epidemiology .....	98
			10.2.1.3	Clinical Features .....	98
			10.2.1.4	Fluorescein Angiography .....	99
			10.2.1.5	Ultrasonography .....	100
			10.2.2	Special Investigations .....	100
			10.2.2.1	Neuroradiology .....	100
			10.2.2.2	Cerebrospinal Fluid Analysis .....	101
			10.2.3	Tissue Biopsy .....	101

10.2.3.1	Vitreous Sampling.....	101	10.2.9	Leukaemias .....	107
10.2.3.2	Other Tissue Sampling Techniques ....	101	10.2.10	Paraproteinaemias .....	107
10.2.4	Tissue Analysis Techniques .....	101	10.3	Nonlymphoproliferative	
10.2.4.1	Cytology .....	101		Malignancies.....	108
10.2.4.2	Immunohistochemistry.....	102	10.3.1	Uveal Melanoma .....	108
10.2.4.3	Cytokines .....	103	10.3.1.1	Clinical Features.....	108
10.2.4.4	Molecular Analysis .....	103	10.3.1.2	Diagnosis .....	108
10.2.5	Treatment.....	103	10.3.1.3	Management .....	108
10.2.5.1	Radiation Therapy.....	103	10.3.2	Retinoblastoma .....	109
10.2.5.2	Chemotherapy .....	103	10.3.2.1	Clinical Features.....	109
10.2.5.3	Combination Chemotherapy		10.3.2.2	Diagnosis .....	109
	and Radiotherapy .....	104	10.3.2.3	Management .....	109
10.2.6	Prognosis .....	104	10.3.3	Ocular Metastases.....	110
10.2.7	Primary Uveal Lymphoma .....	104	10.3.3.1	Clinical Features.....	110
10.2.8	Secondary Intraocular		10.3.3.2	Diagnosis .....	110
	Lymphomas.....	105	10.3.4	Juvenile Xanthogranuloma .....	111
10.2.8.1	Diffuse Large B-Cell		10.3.4.1	Clinical Features.....	111
	Lymphoma.....	106	10.3.4.2	Diagnosis .....	111
10.2.8.2	Intravascular B-Cell		10.3.4.3	Management .....	111
	Lymphoma (Malignant			References .....	112
	Angioendotheliomatosis).....	106			
10.2.8.3	T or T/Nk-Cell Lymphomas.....	106	<b>Index</b> .....		117

<http://www.springer.com/978-3-540-69458-8>

Uveitis and Immunological Disorders

Progress III

Pleyer, U.; Forrester, J.V. (Eds.)

2009, XIV, 120 p. 30 illus., 23 illus. in color., Hardcover

ISBN: 978-3-540-69458-8